|
Company data displayed is for sample purposes only and may not reflect the most current information available on Emerging Markets Information Service (EMIS).
Dr. Chip Biotechnology Inc. (晶宇生物科技实业)
Main Activities: Chemical Manufacturing
 |
Please check the full coverage of information what EMIS can offer you. | SEE SAMPLE |
Company Information |
|
Full name Dr. Chip Biotechnology Inc. (晶宇生物科技实业) Headquarters 31, keJung Rd., SBIP, ChuNan, MiaoLi Hsien, Taiwan; Miaoli County; Miaoli County |
Status: Listed Legal Form: Public Limited Company Operational Status: Operational Financial Auditors: Deloitte Touche Tohmatsu (2013) Incorporation Date: October 22, 1998 Total Employees: 35 Tel: 886-37-585585 |
|
Company Description |
| Jingyu Biotechnology Industry was established in 1998.It deals with the R&D,manufacturing and sales of nuclei acid extraction kits,polyÃ,Š,chain reaction polymerization ,rapid nuclei acid hybridization device and bio-chips and other related products. In May 1999 it developed the first Enterovirus test chip and the first equipment to accelerate nuclei acids in the world. In August 1999 it studied the equipment and techniques of rapid nuclei acid hybridization. In October 2000,it studied the | ||
|
||
Company Analysis |
| According to the Individual - Audited financial statement for the first three cumulated quarters of 2012, total net operating revenues decreased with -23.34%, from TWD 29.61 millions to TWD 22.7 millions. Operating result decreased from TWD -20.84 millions to TWD -22.83 millions which means -9.55% change. The results of the period decreased -9.55% reaching TWD -22.83 millions at the end of the period against TWD -20.84 millions last year. Return on equity (Net income/Total equity) went from -7.14% to -8.82%, the Return On Asset (Net income / Total Asset) went from -6.91% to -8.49% and the Net Profit Margin (Net Income/Net Sales) went from -70.38% to -100.57% when compared to the same period of last year. The Debt to Equity Ratio (Total Liabilities/Equity) was 3.95% compared to 3.30% of last year. Finally, the Current Ratio (Current Assets/Current Liabilities) went from 18.50 to 14.75 when compared to the previous year. |
Key Executives |
|
|||||
|
|||||
|
|||||
Companies with Similar Main Activities |
FULL COMPANY PROFILE
|
|
2012 Q3C (non-cons) |
2012 Q2C (non-cons) |
|
 | ||
| Audited | Audited | |
| ||
| TW Listed Company Financials | TW Listed Company Financials | |
| ||
| Unit | Millions | Millions |
| ||
Balance Sheet
| ||
Total Assets |
269 |
271 |
| ||
Current Assets |
149 |
149 |
| ||
Total Liabilities |
10 |
7 |
| ||
Shareholders Equity |
258 |
264 |
| ||
Current Liabilities |
10 |
7 |
| ||
| * All the accounts are in TWD. | ||
Income Statement
| ||
Total Operating Revenue |
22 |
13 |
| ||
Operational Profit (Loss) |
-22 |
-17 |
| ||
Net Profit (Loss) |
-22 |
-17 |
| ||
| * All the accounts are in TWD. | ||
Ratios
| Profitability Ratios | ||
| ||
Return on Assets (ROA) |
-8.49% |
-6.28% |
| ||
Annualised Return on Assets (ROA) |
-11.32% |
-12.56% |
| ||
Return on Equity (ROE) |
-8.82% |
-6.46% |
| ||
Annualised Return on Equity (ROE) |
-11.76% |
-12.92% |
| ||
Return on Sales (ROS) |
-100.57% |
-129.2% |
| ||
Return on Capital |
-8.82% |
-6.46% |
| ||
Gross Profit Margin |
53.52% |
62.41% |
| ||
Operating Profit Margin |
-124.8% |
-135.7% |
| Efficiency Ratios | ||
| ||
Accounts Receivable Turnover |
4.50x |
6.71x |
| ||
Inventory Turnover |
1.02x |
0.46x |
| ||
Current asset turnover |
0.15x |
0.09x |
| ||
Fixed-asset turnover |
0.24x |
0.14x |
| ||
Asset Turnover |
0.08x |
0.05x |
| Valuation figures and ratios | ||
| ||
Earning Before Interests and Taxes (EBIT) |
-22 |
-17 |
| ||
EBITDA |
-14 |
-11 |
| ||
Enterprise value |
585 |
488 |
| ||
Enterprise Value / EBITDA |
-39.23 |
-41.46 |
| ||
Bookvalue (BV) |
251 |
257 |
| ||
Net Cash |
81 |
102 |
| Liquidity Ratios | ||
| ||
Current Ratio |
1,474.98% |
2,103.94% |
| ||
Quick ratio |
1,373.1% |
1,952.88% |
| ||
Doom's day ratio |
903.56% |
1,546.84% |
| ||
Cash Flow to Debt |
-314.2% |
-198.61% |
| Leverage Ratios | ||
| ||
Leverage ratio |
103.95% |
102.73% |
| ||
Debt to equity |
3.95% |
2.73% |
| ||
Debt to total assets |
3.8% |
2.65% |
| ||
Debt / Enterprise Value |
1.74% |
1.48% |
| Market ratios | ||
| ||
Market Cap / Net cash |
8.21 |
5.76 |
| Trend Ratios | ||
| ||
Revenue Trend |
76.66% |
68.04% |
| ||
Net Income Trend |
109.55% |
115.64% |
| ||
Operating Income Trend |
114.92% |
115.3% |
| ||
 |